Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU

NCT00005036 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00005036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Completed
Start date
November 30, 1999
Completion date
Not reported
Enrollment
560 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mucinous adenocarcinoma of the colon, mucinous adenocarcinoma of the rectum, recurrent colon cancer, recurrent rectal cancer, signet ring adenocarcinoma of the colon, signet ring adenocarcinoma of the rectum, stage iiia colon cancer, stage iiia rectal cancer, stage iiib colon cancer, stage iiib rectal cancer, stage iiic colon cancer, stage iiic rectal cancer, stage iva colon cancer, stage iva rectal cancer, stage ivb colon cancer, stage ivb rectal cancer